MSD Korea launches 9-valent cervical cancer, Gardasil 9

Published: 2016-07-27 12:45:23

Updated: 2016-07-27 12:45:23

MSD Korea(CEO Avi Ben-Shoshan) announced a launch of its cervical cancer vaccine Gardasil 9(9-valent human papillomavirus vaccine). Gardasil 9 acquired domestic commercialization approval from the Ministry of Food and Drug Safety(MFDS) last January.

Gardasil 9, a 9-valent HPV recombinant vaccine which prevents diseases inducing HPV type 6, 11, 16, 18, 31, 33, 45, 52 & 58, has had the highest n...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.